Ex-Genzyme Chief Henri Termeer Signs On As Sarepta Advisor

Xconomy Boston — 

Sarepta Therapeutics (NASDAQ: SRPT) of Cambridge, MA, has hired former Genzyme head Henri Termeer as an advisor as the company waits for word from FDA about its Duchenne muscular dystrophy treatment eteplirsen. As Xconomy reported Monday, Sarepta has asked the agency to start its final review of eteplirsen and decide whether the drug should come to market as a treatment for one version of the rare DMD that affects about 2,000 patients in the U.S. In a statement, Termeer, with decades of experience bringing drugs to market for rare diseases, said he would work with Sarepta on eteplirsen as well as other drugs in its pipeline.